Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 8/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23558300 | 0.83 | PPM1D (0.37) | CNR1CNR2ACACBMMP13 | |
| SCHEMBL25863741 | 0.79 | ACACB (0.37) | CNR1CNR2ACACBMMP13HSD17B1 | |
| SCHEMBL25856816 | 0.79 | ACACB (0.35) | CNR1CNR2ACACBHSD17B1HSD17B2 | |
| SCHEMBL23524256 | 0.71 | MAPT (0.47) | CNR1CNR2MAPT | |
| SCHEMBL30355725 | 0.71 | PPARA (0.37) | CNR1CNR2MAPT | |
| SCHEMBL30355367 | 0.71 | MAPT (0.47) | CNR1CNR2MAPT | |
| SCHEMBL23524175 | 0.71 | PPARA (0.37) | CNR1CNR2MAPT | |
| SCHEMBL25856660 | 0.71 | CNR1 (0.39) | CNR1CNR2MAPT | |
| SCHEMBL23558458 | 0.71 | MMP13 (0.40) | ACACBMMP13HSD17B1HSD17B2ENPP3 | |
| SCHEMBL23558464 | 0.70 | ACACB (0.37) | ACACBHSD17B1HSD17B2ENPP3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | CNR1 20/4885CNR2 38/4885ACACB 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.